Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...
Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...
The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...
What Hims & Hers stock could be witnessing now is a short-squeeze. As its stock began rising sharply, short-sellers move to get out. So over the past week, we’ve seen shares surge 60%. In midday ...